Update date
01 Apr 2026
Genenta Science S.p.A. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
- Public ticker
- GNTA on Nasdaq
- Latest financial report
- 01 Apr 2026
- Company location
- Milan, Italy
Shareable Research Card
GNTA - Genenta Science S.p.A. Financial Facts
GNTA - Genenta Science S.p.A. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q4 2025
- Latest reported value
- Current Ratio 14.16x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for GNTA - Genenta Science S.p.A.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 01 Apr 2026.
Benchmark Context
How Current Ratio compares
Current Ratio is up about 105% versus the comparable prior period.
Compared with
Compared with Genenta Science S.p.A.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q4 2025.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- GNTA - Genenta Science S.p.A. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Current Ratio 14.16x.
Change
- Current Ratio YoY change: +105%.
- Most recent SEC facts end date: 31 Dec 2025.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2025-12-31) highlights Current Ratio 14.16x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-418%
fair value gap
Fair value per share
$4.80
Market price
$1.51
GNTA - Local security
PEG ratio
n/a
Enterprise value
$100.13M
Equity value
$94.6M
DCF fair value scenarios
Bear
$3.51
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -333%
Base
$4.80
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -418%
Bull
$6.83
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -552%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Revenue is unavailable or not positive
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Ebitda is unavailable or not positive
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
n/a
Local security market cap / SEC revenue
Revenue is unavailable or not positive
P/B
1.4x
Local security market cap / SEC equity
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $6.88M
- Trailing SEC FCF
- Reported FCF
- $6.88M
- Net income
- $6.53M
- EBITDA
- $6.58M
- Cash
- $5.53M
- Debt
- n/a
- Equity
- $21.84M
- Shares
- 19,710,187
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
14.1/100
Weak Confidence low
Financial Health
- Current Ratio
- 14.16x
Strengths
No strong signals yet.
Watchpoints
Current Ratio
Key metrics snapshot
Current Ratio
14.16x
YoY: +105%
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 14.16x | +105% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 23,432,183 | +28% |
| Common Stock, Shares, Outstanding | 23,432,183 | +28% |
| Common Stock, Value, Issued | €84,259,476 | +23% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY change |
|---|---|---|
| Accumulated Other Comprehensive Income (Loss), Net of Tax | €166,511 | +87% |
| Assets | €31,889,310 | +115% |
| Assets, Current | €29,979,552 | +107% |
| Cash and Cash Equivalents, at Carrying Value | €5,527,672 | +21% |
| Common Stock, Par or Stated Value Per Share | 0 | |
| Common Stock, Shares Authorized | 59,700,000 | 0% |
| Common Stock, Shares, Issued | 23,432,183 | +28% |
| Deferred Tax Assets, Gross | €16,570,239 | +14% |
| Deferred Tax Assets, Operating Loss Carryforwards | €16,084,600 | +16% |
| Deferred Tax Assets, Valuation Allowance | €16,570,239 | +14% |
| Employee-related Liabilities, Current | €71,996 | |
| Liabilities and Equity | €31,889,310 | +115% |
| Liabilities, Current | €2,117,885 | +0.88% |
| Marketable Securities, Current | €22,621,518 | +180% |
| Property, Plant and Equipment, Gross | €148,870 | +5.4% |
| Property, Plant and Equipment, Net | €22,465 | -48% |
| Retained Earnings (Accumulated Deficit) | €62,585,347 | -12% |
| Stockholders' Equity Attributable to Parent | €21,840,640 | +75% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first